- Company
- Samil, a series of love calls from multinational companies
- by Lee, Seok-Jun May 16, 2023 12:16am
- Samil Pharmaceutical is receiving a series of love calls from multinational companies. This time, it has decided to exclusively distribute and sell all Sandoz products, including the central nervous system (CNS). The CNS division, which was newly established in 2021, will gain momentum for business expansion. It is evaluated that Samil Pharma
- Company
- New diabetes treatment guidelines released
- by Kim, Jin-Gu May 15, 2023 05:41am
- The status of GLP-1 analogues and SGLT-2 inhibitors has risen further in Korea’s new diabetes treatment guidelines. In the revised guidelines, when considering options to use in combination with injection therapy, GLP-1 analogues were recommended over basal insulin, and SGLT-2 inhibitors were recommended first for diabetic patients with hear
- Company
- MSD Korea begins voluntary retirement
- by Jung, Sae-Im May 15, 2023 05:40am
- MSD Korea, which announced a reduction in manpower due to the abolition of the Januvia division, has begun a full-fledged reduction in personnel by disclosing the conditions for ERP. The labor union of MSD Korea warned of a tough response, saying, "We cannot accept the company's attempt to reduce manpower." On the 12th, MSD Korea announced t
- Company
- Advate leading hemophilia treatment
- by Nho, Byung Chul May 12, 2023 05:45am
- In the field of hemophilia non-antibody and antibody treatment, Takeda Korea Pharmaceutical and JW Pharmaceutical are gaining attention as they are strengthening their positions. Korea Takeda Pharmaceutical's 'Advate/Adynovate', and JW Pharmaceutical's Hemlibra's sales last year were 26.2 billion won and 7.6 billion won, respectively, ran
- Company
- SK Biopharm’s cenobamate secures KRW 700 billion
- by Chon, Seung-Hyun May 12, 2023 05:45am
- Cumulative sales of SK Biopharmaceutical’s epilepsy treatment cenobamate exceeded KRW 300 billion in the US. It had continued to show growth every quarter ever since its release. Combined with the upfront payment and milestone payments cenobamate has earned more than KRW 700 billion over the past 4 years. According to SK Biopharm on the 11th
- Company
- SU's strengths maximized through combined use with SGLT-2is
- by Kim, Jin-Gu May 12, 2023 05:44am
- New opportunities have emerged for the use of the diabetes treatment sulfonylurea (SU). It is claimed that its combined use with SGLT-2 inhibitor drugs can offset the existing disadvantages such as hypoglycemia and weight gain, while fully utilizing the strong blood sugar lowering effect of SU drugs. Professor Jin Hwa Kim of the Depart
- Company
- Scemblix can be prescribed at general hospitals
- by Eo, Yun-Ho May 11, 2023 05:48am
- Novartis' new chronic myelogenous leukemia drug Scemblix is entering prescription rights in general hospitals. According to related industries, Novartis Korea's Ph+CML Philadelphia chromosome-positive chronic myeloid leukemia treatment drug Scemblix has been approved by the Drug Committee (DC) of medical institutions such as Seoul St. Mary
- Company
- Scemblix can be prescribed at general hospitals
- by Eo, Yun-Ho May 10, 2023 11:18pm
- Novartis' new chronic myelogenous leukemia drug Scemblix is entering prescription rights in general hospitals. According to related industries, Novartis Korea's Ph+CML Philadelphia chromosome-positive chronic myeloid leukemia treatment drug Scemblix has been approved by the Drug Committee (DC) of medical institutions such as Seoul St. Mar
- Company
- Negotiation on the price of Onureg has started
- by Eo, Yun-Ho May 10, 2023 11:17pm
- Suggestion of treatment options for patients unable to undergo hematopoietic stem cell transplantation Onureg, an acute myelogenous leukemia maintenance treatment drug, recently entered into drug price negotiations for insurance coverage. After passing the HIRA Cancer Disease Review Committee in December of last year and the Pharmaceutica
- Company
- Forxiga, has the largest number of clinical trials
- by Jung, Sae-Im May 10, 2023 05:58am
- With the expansion of SGLT-2 inhibitor coverage, which began in April, combination prescriptions of various diabetes drugs and SGLT-2 drugs are expected to increase. However, as the clinical basis for each drug is a prerequisite for the expansion of this benefit, there are differences in detailed application depending on the presence or absence
